Portal de Periódicos da CAPES

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer

2018; Cell Press; Volume: 173; Issue: 7 Linguagem: Inglês

10.1016/j.cell.2018.04.034

1097-4172

Yi-Mi Wu, Marcin Cieślik, Robert J. Lonigro, Pankaj Vats, Melissa A. Reimers, Xuhong Cao, Ning Yu, Lisha Wang, Lakshmi P. Kunju, Navonil De Sarkar, Elisabeth I. Heath, Jonathan Chou, Felix Y. Feng, Peter S. Nelson, Johann S. de Bono, Weiping Zou, Bruce Montgomery, Ajjai Alva, Dan R. Robinson, Arul M. Chinnaiyan,

Ubiquitin and proteasome pathways

Using integrative genomic analysis of 360 metastatic castration-resistant prostate cancer (mCRPC) samples, we identified a novel subtype of prostate cancer typified by biallelic loss of CDK12 that is mutually exclusive with tumors driven by DNA repair deficiency, ETS fusions, and SPOP mutations. CDK12 loss is enriched in mCRPC relative to clinically localized disease and characterized by focal tandem duplications (FTDs) that lead to increased gene fusions and marked differential gene expression. FTDs associated with CDK12 loss result in highly recurrent gains at loci of genes involved in the cell cycle and DNA replication. CDK12 mutant cases are baseline diploid and do not exhibit DNA mutational signatures linked to defects in homologous recombination. CDK12 mutant cases are associated with elevated neoantigen burden ensuing from fusion-induced chimeric open reading frames and increased tumor T cell infiltration/clonal expansion. CDK12 inactivation thereby defines a distinct class of mCRPC that may benefit from immune checkpoint immunotherapy.